HLF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Herbalife Ltd is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive developments, such as the acquisition of Bioniq and a slight revenue growth in Q4 2025, the company's declining net income, EPS, and gross margin, combined with a lack of strong technical or trading signals, suggest that the stock does not currently present a compelling entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 37.043, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 14.504, but no strong bullish signals are present.
Herbalife announced the acquisition of Bioniq for $55 million to enhance its personalized nutrition offerings, which could drive future growth. Analysts from Citi and Maxim have provided positive ratings and price targets, citing strong Q4 performance and a sustainable business model.
Net income and EPS have significantly declined YoY in Q4 2025, indicating profitability challenges. Gross margin also dropped slightly. Analysts like BofA and Mizuho remain cautious, citing weak fundamentals and competitive pressures. Technical indicators do not show a strong bullish trend.
In Q4 2025, revenue increased by 6.26% YoY to $1.283 billion. However, net income dropped by 52% YoY to $85.4 million, and EPS fell by 53.45% YoY to $0.81. Gross margin decreased slightly to 77.53%.
Analyst ratings are mixed. Citi and Maxim are optimistic, with price targets of $21 and $20, respectively, citing strong Q4 performance and a turnaround. However, BofA maintains an Underperform rating with a $9 target, and Mizuho is Neutral with a $13 target, citing weak fundamentals and macro uncertainties.
